AbbVie's Parkinson's drug Duopa OK'd in US
AbbVie disclosed on 12 January the FDA had approved Duopa, an enteral suspension formulation of carbidopa and levodopa, as a treatment for motor fluctuations in patients with advanced Parkinson's disease.
AbbVie disclosed on 12 January the FDA had approved Duopa, an enteral suspension formulation of carbidopa and levodopa, as a treatment for motor fluctuations in patients with advanced Parkinson's disease.